NK cell recovery after CD19.CAR-T cell therapy in systemic sclerosis with pulmonary fibrosis: A case study
Introduction: Standard therapy of Systemic Sclerosis (SSc)-associated interstitial lung disease (ILD) can not cure, but only decelerate disease progression. CD19-targeting CAR-T cells have the potential to revolutionize anti-rheumatic therapies by eliminating autoantibodies, yet their effects on downstream [for full text, please go to the a.m. URL]
Institutions
- TU Dortmund University (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Düsseldorf University Hospital (DE)
- Leibniz Research Centre for Working Environment and Human Factors (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-18
- DOI
- https://doi.org/10.3205/24dgrh023
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00